EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Are Calculated Immune Markers with or Without Comorbidities Good Predictors of Colorectal Cancer Survival? The Results of a Longitudinal Study

Zoltan Herold iD, Magdolna Herold iD, Gyongyver Szentmartoni iD, Reka Szalasy, Julia Lohinszky, Aniko Somogyi, Attila Marcell Szasz, Magdolna Dank iD

Medical Sciences · 01.08.2025 · 13 (3) · 108

DOI: 10.3390/medsci13030108 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medical Sciences, online erschienen am 01.08.2025. Verfasst von Zoltan Herold und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1082 Budapest, Hungary. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Excellence and Innovation Office of Hungary.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Although numerous prognostic biomarkers have been proposed for colorectal cancer (CRC), their longitudinal evaluation remains limited. The aim of this study was to investigate longitudinal changes in biomarkers calculated from routinely used laboratory markers and their relationships to common chronic diseases (comorbidities).

Methods

A retrospective longitudinal observational study was completed with the inclusion of 817 CRC patients and a total of 4542 measurement points. Pan-immune inflammation value (PIV), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII) were calculated based on complete blood count and albumin measurement data.

Results

Longitudinal data analyses confirmed the different values and slopes of the parameters tested at the different endpoints. Survivors had the lowest and most constant PIVs and SII values, and the highest and most slowly decreasing PNI values. Those patients with non-cancerous death had similar values to the previous cohort, but an increase/decrease occurred towards the death event. Patients with CRC-related death had significantly higher PIVs and SII values and significantly lower PNI values (p < 0.0001), and a significant increase/decrease was observed at the early observational periods. The presence of lymph node and/or distant metastases, adjuvant chemotherapy, and hypertension significantly affected PIVs and SII and/or PNI values. The changes in PIVs and SII and PNI values toward pathological values are poor prognostic signs (p < 0.0001).

Conclusions

Each of the three calculated markers demonstrates suitability for longitudinal patient follow-up, and their pathological alterations over time serve as valuable prognostic indicators. They may also be useful to detect certain clinicopathological parameters early.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBiomarkers, TumorHumansMaleFemaleLongitudinal StudiesMiddle AgedAgedRetrospective StudiesPrognosisComorbidityAdultAged, 80 and over

Stichwörter der Autor:innen

colorectal neoplasmslongitudinal analysispan-immune inflammation valueprognostic nutritional indexsystemic immune-inflammation index

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1082 Budapest, Hungary.
  • Department of Internal Medicine and Hematology, Semmelweis University, 1088 Budapest, Hungary.
  • Department of Medical Oncology, Semmelweis University, 1122 Budapest, Hungary.
  • National Institute of Oncology, 1122 Budapest, Hungary.

ORCID-Profile: Zoltan Herold, Magdolna Herold, Gyongyver Szentmartoni, Magdolna Dank

Förderung

  • National Research, Excellence and Innovation Office of Hungary

Zitieren

APA

Herold, Z., Herold, M., Szentmartoni, G., Szalasy, R., Lohinszky, J., Somogyi, A., Szasz, A. M., & Dank, M. (2025). Are Calculated Immune Markers with or Without Comorbidities Good Predictors of Colorectal Cancer Survival? The Results of a Longitudinal Study. Medical Sciences, 13(3), 108. https://doi.org/10.3390/medsci13030108

Vancouver

Herold Z, Herold M, Szentmartoni G, Szalasy R, Lohinszky J, Somogyi A, et al. Are Calculated Immune Markers with or Without Comorbidities Good Predictors of Colorectal Cancer Survival? The Results of a Longitudinal Study. Medical Sciences. 2025;13(3):108. doi:10.3390/medsci13030108

BibTeX
@article{Herold2025,
  author = {Herold, Zoltan and Herold, Magdolna and Szentmartoni, Gyongyver and Szalasy, Reka and Lohinszky, Julia and Somogyi, Aniko and Szasz, Attila Marcell and Dank, Magdolna},
  title = {Are Calculated Immune Markers with or Without Comorbidities Good Predictors of Colorectal Cancer Survival? The Results of a Longitudinal Study},
  journal = {Medical Sciences},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {108},
  doi = {10.3390/medsci13030108}
}
Kostenlos starten →